Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Pathologic findings at surgery

From: A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

  Standard
(N = 16)
Experimental
(N = 14)
p value
RCB-0 and RCB-I 10 (62.5%) 14 (100.0%) 0.0035
ER negative 8 6  
ER positive 2 8  
RCB-II and RCB-III 6 (37.5%) 0 (0.0%)  
ER negative 0 0  
ER positive 6 0  
pCR 10 (62.5%) 12 (85.7%) 0.0660
ER negative 8 6  
ER positive 2 6  
  1. RCB was pathologically determined from the (1) tumor bed dimensions, (2) cellularity of the invasive cancer, (3) size of largest nodal metastasis, and (4) number of positive lymph nodes. RCB was categorized as RCB-0 = no residual disease, RCB-I = minimal residual disease, RCB-II = moderate residual disease, and RCB-III = extensive residual disease [14]. RCB-0 was synonymous with pCR, indicating no residual disease present in the breast or axilla